cGxP.wire https://validator.w3.org/feed/docs/rss2.html Tonix Pharmaceuticals Reports Phase 3 Data Showing TONMYA® Improved Physical Symptoms and Functional Ability in Fibromyalgia Anixa Biosciences Completes Fifth Ovarian Cancer CAR-T Cohort Vantive Expands HomeAdvantage to Advance Home Dialysis Merck’s KEYTRUDA Monotherapy Reduces Risk of Disease Progression or Death by 43% in Advanced or Recurrent dMMR Endometrial Cancer Pfizer’s TALZENNA Plus XTANDI Receives FDA Approval for Earlier Treatment of Metastatic Prostate Cancer Aptar Pharma Acquires PULMOTREE to Expand Next-Generation Pulmonary Drug Delivery Capabilities Mirum Pharmaceuticals Reports Positive PROGRESS Study Results for ATEBRIOZ in Children with Fibrodysplasia Ossificans Progressiva Daiichi Sankyo and AstraZeneca Announce EU Approval of Enhertu® as Adjuvant Treatment for HER2-Positive Early Breast Cancer Purespring Therapeutics Advances PS-003 Kidney-Targeted Gene Therapy Towards Clinical Development for X-Linked Alport Syndrome Roche Receives CE Mark for cobas® smart e Immunoanalyser to Expand Decentralised Diagnostics Propanc Biopharma Reports PRP Reverses Chemotherapy Resistance in Preclinical Pancreatic Cancer Models Ambros Therapeutics Plans Interim Analysis of Phase 3 Neridronate Trial Following FDA Alignment Medicenna Reports Up to Fourfold Survival Extension With MDNA209 in Preclinical Autoimmune Disease Models 23andMe Analysis Finds Medically Actionable Genetic Results in 10.6% of Nearly 6 Million Participants Octane Biotech and Currus Biologics Automate CUR-001 CAR T-Cell Manufacturing Merck Reports 32% Lower Risk of Death With Sac-TMT in Advanced Endometrial Cancer Bayer Wins China Approval for Asundexian to Prevent Stroke Ascletis Submits FDA Application for Oral Obesity Drug ASC39 Innovent Advances Sintilimab Combination for Melanoma Review Lilly Reports Durable Olomorasib Activity in KRAS Lung Cancer J&J Reports 77% Response in Advanced Head and Neck Cancer Kelun-Biotech Reports Phase 3 Lung Cancer Trial Results Data Amgen Reports 58% Lower Death Risk in Lung Cancer Trial Data GSK Reports Positive Mo-Rez Data in Ovarian Cancer Trial Takeda Reports Phase 3 Success for Arcotatug in Gastric Cancer BeOne Reports Long-Term Survival Benefit in HER2+ GEA Cancer GSK Reports 76% Response With Jemperli in Rectal Cancer Regeneron Reports Long-Term Libtayo Survival Benefits in Skin Cancer Akeso and Summit Therapeutics Report Ivonescimab Survival Gains in Biliary Cancer Can-Fite Reports Positive Final Phase IIa Data for Namodenoson in Advanced Pancreatic Cancer Longeveron Reports Significant Reduction in Major Adverse Cardiac Events in ELPIS II HLHS Trial Roche Reports Survival Gains With Divarasib in Lung Cancer Alebund and R1 Advance AP306 Phase 2b Kidney Trial Serapha Bio Reports Positive Interim Safety and Efficacy Results for SERP-01 in Alpha-1 Antitrypsin Deficiency Innovent Reports IBI363 Data Across Lung and Gastric Cancers Marengo Reports Phase 2 Results for Invikafusp Alfa Intensity Therapeutics Reports Early INVINCIBLE-4 Cancer Data MacroGenics Reports 25% Response Rate for Lorigerlimab in CCGC Pfizer Reports Phase 2 Results for 25-Valent Pediatric Vaccine Frontier Reports FMC-376 Responses in KRAS G12C Lung Cancer Abbott Advances Colorectal Cancer Detection With Oncodetect PureTech Reports Phase 1b LYT-200 Results in High-Risk MDS Ractigen Advances Extrahepatic RNA Delivery With LiCO NovaBridge Reports Mature Phase 1b Data for Givastomig Jazz Pharmaceuticals Reports Long-Term Ziihera Cancer Survival Data Genmab Reports 28.2-Month Median OS With Petosemtamab in HNSCC Amarin Reports EMT2 Trial Survival Benefit With Icosapent Ethyl UCB Funds New Medicine Evaluation Research Chair at Brigham SystImmune and Bristol Myers Squibb Announce Positive PANKU-Lung01 Trial Results AbbVie Wins FDA Approval for SKYRIZI Crohn’s Treatment